COPD—more than just tobacco smoke

医学 慢性阻塞性肺病 慢性支气管炎 肺活量测定 罗氟司特 重症监护医学 戒烟 支气管炎 肺病 疾病 内科学 哮喘 病理
作者
The Lancet
标识
DOI:10.1016/s0140-6736(09)61535-x
摘要

On Sept 12–16, Vienna hosts the European Respiratory Society's annual congress, the largest in pulmonary medicine in the world. As a prelude to the meeting, The Lancet today is devoted to chronic obstructive pulmonary disease (COPD). WHO estimates that 210 million people have COPD worldwide. This number could be higher because many people with COPD often do not seek medical help until the disease worsens. COPD is now an umbrella term to cover emphysema and chronic bronchitis, among others, all of which used to be considered separate conditions. The disease is the fourth leading cause of death in the world, but by 2030 it is expected to be the third, behind ischaemic heart disease and cerebrovascular disease. With such a high burden, emphasis on better diagnosis, management, and identification of at-risk groups must be achieved. In today's issue, Joan Soriano and colleagues review spirometry, the mainstay of diagnosis. They call for better screening with spirometry, because early detection correlates with better outcomes. Spirometry is also used to classify COPD into four subgroups—mild, moderate, severe, and very severe. This classification helps guide the type of treatment options offered. For most patients, longacting inhaled β2 agonists, inhaled antimuscarinics, and inhaled corticosteroids in differing combinations are the foundation of effective management. Treatment with the anti-inflammatory phosphodiesterase-4 inhibitor roflumilast is presented in two randomised trials from Peter Calverley's group. The overall findings of the two studies suggest that there is benefit to patients with COPD, with a reduction in exacerbations, and improvement in lung function, when roflumilast is combined with a longacting bronchodilator or longacting inhaled antimuscarinics. For a long time COPD has been thought of as a smokers' disease, and not without reason. Those who smoke damage their lungs and create the pathophysiological environment for this disease. However, as Holger Schünemann points out in a Comment in today's issue, a worldwide ban on tobacco would indeed benefit health substantially both at the population and individual level—yet the world is not ready for such a bold ban. Sundeep Salvi and Barnes explore the aetiology of COPD and highlight the need for greater focus on risk factors other than smoking. They argue that smoking is not the biggest risk factor for COPD, and that this has been reported as early as 1963. Interest in COPD in non-smokers has increased in the past 5 years, although smoking has still remained the emphasis of most research. The Global initiative for chronic Obstructive Lung Disease (GOLD) points out in its guidelines that COPD is caused by “Tobacco smoke, occupational dusts and chemicals, indoor air pollution and outdoor air pollution”, putting these inhalation exposures under one blanket. Salvi and Barnes take this further, listing indoor air pollution from biomass fuel, pulmonary tuberculosis, chronic asthma, and socioeconomic status as additional risk factors in the development of COPD. Previous evidence suggests that occupational exposure to different compounds can lead to long-term severe sequelae in the respiratory system (eg, asbestos and mesothelioma); therefore, it is not a great leap to think that occupational exposures are also important risk factors for COPD. In parts of Africa tuberculosis is synonymous with HIV and therefore a diagnosis of either carries a large stigma. If patients with tuberculosis have an increased risk of COPD, could this population be under-represented in this continent? Will patients who have symptoms not present to health-care providers for fear of a diagnosis of tuberculosis, when in fact it is COPD? Education and increased awareness could be an answer for some of these patients, as well as an increased effort to destigmatise the association of tuberculosis and HIV by those health-care professionals working within this community. Chronic asthma is also of interest because it carries a greater risk of developing COPD than that caused by smoking. If asthma development is on the increase around the world, COPD incidence is likely to increase as well, perhaps even more so than the current predictions. Biomass fuel (coal, wood, and charcoal) has an exposed population of 3 billion, compared with 1 billion for those exposed to tobacco—making such fuel an important target in COPD prevention. This problem is not just one for developing countries. Even if over half of those who have COPD are non-smokers, the battle against smoking and health promotion to quit smoking should continue. However, the identification and education of those who are at risk from other inhalation exposures, both at home and at work, especially in developing countries, also needs to become a priority. From BODE to ADO to outcomes in multimorbid COPD patientsThe resources spent on research and treatment into chronic obstructive pulmonary disease (COPD) seem ludicrous compared with what could be achieved by simple and better legislation. In fact, the world needs to ban tobacco. Unfortunately, partly because many policy makers have failed to act appropriately, reality is different. COPD remains a major public health concern and is high on the priority list of major organisations, such as WHO.1 Full-Text PDF Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trialsSince different subsets of patients exist within the broad spectrum of COPD, targeted specific therapies could improve disease management. This possibility should be explored further in prospective studies. Full-Text PDF Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trialsRoflumilast improves lung function in patients with COPD treated with salmeterol or tiotropium, and could become an important treatment for these patients. Full-Text PDF Screening for and early detection of chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease (COPD) is a substantially underdiagnosed disorder, with the diagnosis typically missed or delayed until the condition is advanced. Spirometry is the most frequently used pulmonary function test and enables health professionals to make an objective measurement of airflow obstruction and assess the degree to which it is reversible. As a diagnostic test for COPD, spirometry is a reliable, simple, non-invasive, safe, and non-expensive procedure. Early diagnosis of COPD should provide support for smoking cessation initiatives and lead to reduction of the societal burden of the disease, but definitive confirmation of both proves elusive. Full-Text PDF Chronic obstructive pulmonary disease in non-smokersChronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Tobacco smoking is established as a major risk factor, but emerging evidence suggests that other risk factors are important, especially in developing countries. An estimated 25–45% of patients with COPD have never smoked; the burden of non-smoking COPD is therefore much higher than previously believed. About 3 billion people, half the worldwide population, are exposed to smoke from biomass fuel compared with 1·01 billion people who smoke tobacco, which suggests that exposure to biomass smoke might be the biggest risk factor for COPD globally. Full-Text PDF
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
浅浅完成签到,获得积分10
1秒前
量子星尘发布了新的文献求助10
6秒前
帅气的藏鸟完成签到,获得积分10
10秒前
加油完成签到 ,获得积分10
11秒前
健康的宛菡完成签到 ,获得积分10
12秒前
橙果果发布了新的文献求助20
12秒前
晚晚完成签到,获得积分10
13秒前
13秒前
听闻韬声依旧完成签到 ,获得积分10
13秒前
ZHZ完成签到,获得积分10
14秒前
啊哈啊哈额完成签到,获得积分10
14秒前
yyy完成签到,获得积分10
15秒前
15秒前
xiaoputaor完成签到 ,获得积分10
16秒前
Camus发布了新的文献求助10
16秒前
paper reader完成签到,获得积分10
16秒前
17秒前
八八九九九1完成签到,获得积分10
18秒前
tigger完成签到 ,获得积分10
19秒前
21秒前
23秒前
优雅的千雁完成签到,获得积分10
25秒前
2316690509完成签到 ,获得积分10
25秒前
没用的三轮完成签到,获得积分10
25秒前
fancy完成签到 ,获得积分10
25秒前
mayberichard完成签到,获得积分10
29秒前
LINDENG2004完成签到 ,获得积分10
35秒前
wz完成签到,获得积分10
36秒前
简奥斯汀完成签到 ,获得积分10
43秒前
五本笔记完成签到 ,获得积分10
43秒前
46秒前
花花发布了新的文献求助20
46秒前
asd113发布了新的文献求助10
50秒前
美满的小蘑菇完成签到 ,获得积分10
50秒前
自然白安完成签到 ,获得积分10
56秒前
量子星尘发布了新的文献求助10
59秒前
等待小鸽子完成签到 ,获得积分10
1分钟前
龙虾发票完成签到,获得积分10
1分钟前
小康学弟完成签到 ,获得积分10
1分钟前
了0完成签到 ,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038066
求助须知:如何正确求助?哪些是违规求助? 3575779
关于积分的说明 11373801
捐赠科研通 3305584
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022